To examine whether serum Fibulin-3 and Fibulin-1 levels change with advanced fibrosis in another cohort, we measured the serum Fibulin-3 and serum Fibulin-1 levels in cohort 2 (473 patients with MASLD with biopsy). Here, FBLN1 is linked to metabolic dysfunction-associated steatotic liver disease.